Outer membrane vesicles as versatile tools for therapeutic approaches - PubMed
- ️Fri Jan 01 2021
Outer membrane vesicles as versatile tools for therapeutic approaches
Franz G Zingl et al. Microlife. 2021.
Abstract
Budding of the bacterial surface results in the formation and secretion of outer membrane vesicles, which is a conserved phenomenon observed in Gram-negative bacteria. Recent studies highlight that these sphere-shaped facsimiles of the donor bacterium's surface with enclosed periplasmic content may serve multiple purposes for their host bacterium. These include inter- and intraspecies cell-cell communication, effector delivery to target cells and bacterial adaptation strategies. This review provides a concise overview of potential medical applications to exploit outer membrane vesicles for therapeutic approaches. Due to the fact that outer membrane vesicles resemble the surface of their donor cells, they represent interesting nonliving candidates for vaccine development. Furthermore, bacterial donor species can be genetically engineered to display various proteins and glycans of interest on the outer membrane vesicle surface or in their lumen. Outer membrane vesicles also possess valuable bioreactor features as they have the natural capacity to protect, stabilize and enhance the activity of luminal enzymes. Along these features, outer membrane vesicles not only might be suitable for biotechnological applications but may also enable cell-specific delivery of designed therapeutics as they are efficiently internalized by nonprofessional phagocytes. Finally, outer membrane vesicles are potent modulators of our immune system with pro- and anti-inflammatory properties. A deeper understanding of immunoregulatory effects provoked by different outer membrane vesicles is the basis for their possible future applications ranging from inflammation and immune response modulation to anticancer therapy.
Keywords: OMV; bacterial vesicles; host cell interaction; immunomodulation; inflammation; vaccine development.
© The Author(s) 2021. Published by Oxford University Press on behalf of FEMS.
Conflict of interest statement
None declared.
Figures

Overview of the therapeutic potential of OMVs. OMVs are released from bacterial cells (green or blue) with natural luminal content (gray). OMVs are recognized by host cell receptors (yellow), i.e. extracellularly via TLRs and in the cytosol after internalization via PRRs, resulting in inflammatory and humoral immune responses. Thus, OMVs could be used to specifically modulate pro- and anti-inflammatory responses. Moreover, OMVs can be used as vaccine candidates derived from an individual bacterial species (green or blue OMVs), derived from multiple species and used as mixtures (green and blue OMVs) or derived from genetically engineered to display heterologously expressed antigens (green OMVs with heterologously expressed antigens in red). Genetic engineering of donor bacterial cells also allows to modulate the composition of OMVs to decorate or load OMVs with heterologously expressed biomolecules (red components in or on OMVs). Applications of such bioengineered OMVs range from biocatalysis and biodegradation to delivery of natural and heterologously effectors to host cells, including targeting of specific host cell types via defined receptor interactions (purple).
Similar articles
-
Ryan R, Hill S. Ryan R, et al. Cochrane Database Syst Rev. 2019 Oct 23;10(10):ED000141. doi: 10.1002/14651858.ED000141. Cochrane Database Syst Rev. 2019. PMID: 31643081 Free PMC article.
-
Depressing time: Waiting, melancholia, and the psychoanalytic practice of care.
Salisbury L, Baraitser L. Salisbury L, et al. In: Kirtsoglou E, Simpson B, editors. The Time of Anthropology: Studies of Contemporary Chronopolitics. Abingdon: Routledge; 2020. Chapter 5. In: Kirtsoglou E, Simpson B, editors. The Time of Anthropology: Studies of Contemporary Chronopolitics. Abingdon: Routledge; 2020. Chapter 5. PMID: 36137063 Free Books & Documents. Review.
-
Using Experience Sampling Methodology to Capture Disclosure Opportunities for Autistic Adults.
Love AMA, Edwards C, Cai RY, Gibbs V. Love AMA, et al. Autism Adulthood. 2023 Dec 1;5(4):389-400. doi: 10.1089/aut.2022.0090. Epub 2023 Dec 12. Autism Adulthood. 2023. PMID: 38116059 Free PMC article.
-
Huang Y, Trollor JN, Foley KR, Arnold SRC. Huang Y, et al. Autism Adulthood. 2023 Dec 1;5(4):423-436. doi: 10.1089/aut.2022.0066. Epub 2023 Dec 12. Autism Adulthood. 2023. PMID: 38116050 Free PMC article.
-
Review of Machine Learning Techniques in Soft Tissue Biomechanics and Biomaterials.
Donmazov S, Saruhan EN, Pekkan K, Piskin S. Donmazov S, et al. Cardiovasc Eng Technol. 2024 Oct;15(5):522-549. doi: 10.1007/s13239-024-00737-y. Epub 2024 Jul 2. Cardiovasc Eng Technol. 2024. PMID: 38956008 Review.
Cited by
-
A molecular toolkit for heterologous protein secretion across Bacteroides species.
Yeh YH, Kelly VW, Pour RR, Sirk SJ. Yeh YH, et al. bioRxiv [Preprint]. 2023 Dec 15:2023.12.14.571725. doi: 10.1101/2023.12.14.571725. bioRxiv. 2023. PMID: 38168418 Free PMC article. Updated. Preprint.
-
Pschunder B, Locati L, López O, Martin Aispuro P, Zurita E, Stuible M, Durocher Y, Hozbor D. Pschunder B, et al. Front Immunol. 2024 Apr 8;15:1387534. doi: 10.3389/fimmu.2024.1387534. eCollection 2024. Front Immunol. 2024. PMID: 38650936 Free PMC article.
-
Krzyżek P, Marinacci B, Vitale I, Grande R. Krzyżek P, et al. Pharmaceutics. 2023 Feb 4;15(2):522. doi: 10.3390/pharmaceutics15020522. Pharmaceutics. 2023. PMID: 36839844 Free PMC article. Review.
-
Thapa HB, Ebenberger SP, Schild S. Thapa HB, et al. Antibiotics (Basel). 2023 Jun 14;12(6):1045. doi: 10.3390/antibiotics12061045. Antibiotics (Basel). 2023. PMID: 37370364 Free PMC article. Review.
-
Thapa HB, Kohl P, Zingl FG, Fleischhacker D, Wolinski H, Kufer TA, Schild S. Thapa HB, et al. Microbiol Spectr. 2023 Aug 17;11(4):e0111523. doi: 10.1128/spectrum.01115-23. Epub 2023 Jun 12. Microbiol Spectr. 2023. PMID: 37306596 Free PMC article.
References
-
- Alaniz RC, Deatherage BL, Lara JCet al. . Membrane vesicles are immunogenic facsimiles of Salmonella typhimurium that potently activate dendritic cells, prime B and T cell responses, and stimulate protective immunity in vivo. J Immunol. 2007;179:7692–701. - PubMed
-
- Alvarez CS, Badia J, Bosch Met al. . Outer membrane vesicles and soluble factors released by probiotic Escherichia coli Nissle 1917 and commensal ECOR63 enhance barrier function by regulating expression of tight junction proteins in intestinal epithelial cells. Front Microbiol. 2016;7:1981. - PMC - PubMed
-
- Alves NJ, Turner KB, Daniele MAet al. . Bacterial nanobioreactors: directing enzyme packaging into bacterial outer membrane vesicles. ACS Appl Mater Interfaces. 2015;7:24963–72. - PubMed
-
- Alves NJ, Moore M, Johnson BJet al. . Environmental decontamination of a chemical warfare simulant utilizing a membrane vesicle-encapsulated phosphotriesterase. ACS Appl Mater Interfaces. 2018;10:15712–9. - PubMed
LinkOut - more resources
Full Text Sources